Mostra el registre parcial de l'element

dc.contributor.authorMora, Toni
dc.contributor.authorSánchez-Collado, Irene
dc.contributor.authorMullol, Joaquim
dc.contributor.authorMuñoz-Cano, Rosa
dc.contributor.authorRibó, Paula
dc.contributor.authorValero, Antonio
dc.date.accessioned2023-09-22T15:03:13Z
dc.date.available2023-09-22T15:03:13Z
dc.date.issued2023
dc.identifier.citationMora, Toni; Sánchez-Collado, Irene; Mullol, Joaquim [et al.]. Prevalence of atopic dermatitis in the adolescent population of Catalonia (Spain). Allergologia etimmunopathologia, 2023, 51(4), p. 101-109. Disponible en: <https://www.all-imm.com/index.php/aei/article/view/893>. Fecha de acceso: 22 sep. 2023. DOI: 10.15586/aei.v51i4.893ca
dc.identifier.issn0301-0546ca
dc.identifier.urihttp://hdl.handle.net/20.500.12328/3825
dc.description.abstractBackground: Studies on the prevalence of atopic dermatitis (AD) for the adolescent cohort in general-based large populations are scarce worldwide. We performed a retrospective population--based observational cohort study of 76,665 adolescent patients diagnosed with AD in Catalonia (Spain). We studied the prevalence of AD by age, gender, disease severity, comorbidities, serum total immunoglobulin E (tIgE) and appropriate medical treatment (AMT) for the Catalan population. Methods: Adolescent individuals (12–17 years) diagnosed with AD by medical records at different health care levels (primary, hospital, emergency) from the Catalan Health System (CHS) were included. Statistical analyses evaluated sociodemographic characteristics, prevalence, comorbidities, serum tIgE and AMT. Results: The overall diagnosed AD prevalence in the adolescent Catalan population (76,665) was 16.9%, being higher for the non-severe (16.7%) than for the severe (0.2%) populations. Topical corticosteroids were the most prescribed drug (49.5%), and the use of all prescribed treatments was higher in severe AD patients, especially systemic corticosteroids (49.7%) and immunosuppressants (45.4%). AD patients had, on average, a serum tIgE of 163.6 KU/L, which was higher for severe than non-severe disease (155.5 KU/L vs 101.9 KU/L, respectively). Allergic rhinitis (15.0%) and asthma (13.5%) were among the most frequent comorbid respiratory and allergy diseases. Conclusions: This is the first Spanish study reporting the overall diagnosed prevalence for a large-scale adolescent cohort (12–17 years old) from Catalonia. It provides new and robust evidence of AD’s prevalence and related characteristics in this region.en
dc.format.extent9ca
dc.language.isoengca
dc.publisherElsevierca
dc.relation.ispartofAllergologia etimmunopathologiaca
dc.relation.ispartofseries51;4
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.en
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.otherDermatitis atòpicaca
dc.subject.otherEstudi epidemiològicca
dc.subject.otherBasat en la poblacióca
dc.subject.otherPrevalençaca
dc.subject.otherGravetatca
dc.subject.otherDermatitis atópicaes
dc.subject.otherEstudio epidemiológicoes
dc.subject.otherBasado en la poblaciónes
dc.subject.otherPredominioes
dc.subject.otherGravedades
dc.subject.otherAtopic dermatitisen
dc.subject.otherEpidemiological studyen
dc.subject.otherPopulation-baseden
dc.subject.otherPrevalenceen
dc.subject.otherSeverityen
dc.titlePrevalence of atopic dermatitis in the adolescent population of Catalonia (Spain)en
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc61ca
dc.subject.udc616.5ca
dc.identifier.doihttps://dx.doi.org/10.15586/aei.v51i4.893ca


Fitxers en aquest element

 

Aquest element apareix en la col·lecció o col·leccions següent(s)

Mostra el registre parcial de l'element

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Excepte que s'indiqui una altra cosa, la llicència de l'ítem es descriu com https://creativecommons.org/licenses/by-nc-nd/4.0/
Comparteix a TwitterComparteix a LinkedinComparteix a FacebookComparteix a TelegramComparteix a WhatsappImprimeix